- In this multi-center randomized clinical trial, the six month rate of in-segment restenosis was more than five times lower for the CYPHER Stent compared to the Taxus Stent (4% vs. 20.8% respectively).
- Most important for patients and physicians, key clinical outcomes measures were about four times lower for the CYPHER Stent -- at nine-months, clinically driven TLR for the CYPHER Stent was 1.5% compared to 6% for the Taxus Stent while the composite clinical endpoint of MACE was 2% for the CYPHER Stent compared to 8% for the Taxus Stent.
- The CYPHER Stent does not have an approved indication for use in patients with diabetes in the United States.

Other headlines for [JNJ]

• MNT Yesterday 08:01am
  Mentor Corp To be acquired by Johnson & Johnson for $31/shr, valued at $1.12B- Mentor will be acquired for approximately $1.07B in a cash tender offer. - The boards of directors of Johnson & Johnson and Mentor more...
  
• JNJ 11/26/2008 01:18am
  Johnson & Johnson Inc FDA issues complete response letter for Ceftobiprole in complicated skin infections- The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. - Ceftobiprole was approved more...
  
• JNJ 11/24/2008 07:50pm
  Johnson & Johnson Inc WSJ looks at emails related to RISPERDAL- Risperdal is an antipsychotic drug. - Emails sent by JNJ in 2001 and 2002 have raised issues of whether the company helped-promote an uapproved use of the more...
  
• OMRI 11/24/2008 06:32am
  Omrix Biopharmaceuticals JNJ confirms intent to purchase OMRI $25/shr cash; deal valued at $438M- Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company and leading more...
  
• JNJ 11/21/2008 02:29pm
  Johnson & Johnson Inc FDA Approves Tapentadol Immediate-Release Tablets For Relief Of Moderate To Severe Acute Pain
  

Healthcare sector headlines

• LHCG Today 08:57am
  LHC Group Guides FY09 EPS $1.90-2.00 v $1.93e, R $450M-$470M v $436.2Me
  
• NPSP Today 08:50am
  NPS Pharmaceuticals Inc. Update: Initiates Phase 3 'STEPS' Study to Confirm GATTEX Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome- Patient enrollment has begun in a Phase 3 registrational study to confirm more...
  
• OCLS Today 08:48am
  Oculus Innovative Sciences Update: Signs development agreement with Bayer Taiwan for Microcyn tech in Taiwanese animal market- As part of the agreement, Bayer Taiwan Co. Ltd. will be responsible for securing Taiwanese more...
  
• TPTX Today 08:47am
  TorreyPines Therapeutics Update: Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia- Announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as more...
  
• CUR Today 08:02am
  Neuralstem Inc Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials- The collaboration will focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with Dr. more...